Medical Hypotheses
Volume 57, Issue 2 , Pages 133-134 , August 2001

Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C

Received 2 August 2000 ,Accepted 5 January 2001.

References 

    REFERENCES
  1. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355–1360
  2. Goh J, Coughlan B, Quinn J, O’Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1999;11:833–838
  3. Elkins LE, Krupp LB, Scherl W. The measurement of fatigue and contributing neuropsychiatric factors. Semin Clin Neuropsych. 2000;5:58–61
  4. Jalan R, Gibson H, Lombard MG. Patients with PBC have central but no peripheral fatigue. Gut. 1996;39:A30
  5. Jones EA. Fatigue associated with chronic liver disease: A riddle wrapped in a mystery inside an enigma. Hepatology. 1995;22:1606–1608
  6. Lebovics E, Seif F, Kim D. Pruritus in chronic hepatitis C; association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci. 1997;42:1094–1099
  7. Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci. 1998;43:2177–2183
  8. Jones EA, Bergsasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003–1006
  9. Jones EA, Herrera J. Pathogenesis of hepatic encephalopathy. (ed) Pathophysiology of Liver Disease. 2000; p. 467–485
  10. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission?. Hepatology. 1997;25:492–494
  11. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain. 1995;61:33–37
  12. Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol. 1992;77:921–924
  13. Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol. 1993;74:3006–3012
  14. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet. 1999;354:397

PII: S0306-9877(00)91287-8

doi: 10.1054/mehy.2000.1287

Medical Hypotheses
Volume 57, Issue 2 , Pages 133-134 , August 2001

Article Tools